33.87

0.47% -0.16

After Hours: 33.87

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Financials Discussions Forecast

Kymera Therapeutics Inc stock is traded at $33.87, with a volume of 505.48K. It is down -0.47% in the last 24 hours and down -10.04% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Previous Close:

$34.03

Open:

$34.05

24h Volume:

505.48K

Relative Volume:

0.93

Market Cap:

$2.20B

Revenue:

$87.56M

Net Income/Loss:

$-167.47M

P/E Ratio:

-14.47

EPS:

-2.34

Net Cash Flow:

$-148.20M

1W Performance:

-3.50%

1M Performance:

-10.04%

6M Performance:

-30.92%

1Y Performance:

-14.40%

1-Day Range:

$32.75

$34.75

1-Week Range:

$32.75

$35.51

52-Week Range:

$29.16

$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

857-285-5314

Address

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Employee

188

Twitter

Next Earnings Date

2025-02-21

Latest SEC Filings

KYMR's Discussions on Twitter

Compare KYMR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYMR Kymera Therapeutics Inc	33.87	2.20B	87.56M	-167.47M	-148.20M	-2.34
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-25	Initiated	Citigroup	Buy
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Market Perform
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Overweight
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-22-24	Initiated	Oppenheimer	Outperform
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

Mar 18, 2025

Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 18, 2025

Mar 15, 2025

Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 15, 2025

Mar 14, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Mar 14, 2025

Mar 13, 2025

Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq

Mar 13, 2025

Mar 11, 2025

(KYMR) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 11, 2025

Mar 07, 2025

Why Kymera Therapeutics’ Stock is Making Waves - TipRanks

Mar 07, 2025

Mar 06, 2025

Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK

Mar 06, 2025

Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St

Mar 06, 2025

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance

Mar 06, 2025

What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World

Mar 06, 2025

Mar 05, 2025

A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily

Mar 05, 2025

New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 05, 2025

Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World

Mar 05, 2025

Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World

Mar 05, 2025

Mar 04, 2025

Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com Australia

Mar 04, 2025

Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025

Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa

Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada

Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India

Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com

Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock - Investing.com

Mar 03, 2025

Kymera Therapeutics announces new performance-based stock plan - Investing.com India

Mar 03, 2025

Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks

Mar 03, 2025

Rhumbline Advisers Acquires 1,861 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 03, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Mar 01, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance

Mar 01, 2025

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat

Mar 01, 2025

Feb 28, 2025

Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat

Feb 28, 2025

Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Feb 28, 2025

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat

Feb 28, 2025

(KYMR) Trading Signals - Stock Traders Daily

Feb 28, 2025

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - TradingView

Feb 28, 2025